Core D - Phyllis GimottyThe Biostatistics Core consists of personnel with biostatistical experience. The goals of the BiostatisticsCore are to provide biostatistical expertise to program project investigators, and through collaboration usestatistical models and other statistical techniques to understand the critical abnormalities in signalingmolecules, pathways, and networks that are pathogenetic in melanoma and that have therapeuticrelevance. The Biostatistics Core faculty and staff have previous experience in melanoma research andextensive experience with the proposed statistical methodologies and their application to the researchstudies proposed in this program project. They will provide expertise in the following areas to support itsresearch objectives: (1) statistical methods to study associations among gene-related factors and/oramong associated protein-related factors, as well as factors that influence tumor growth in differentbiological models; (2) statistical design and evaluation strategies to assess the impact of experimentalinterventions in genes on relevant biological outcomes (cell apoptosis, tumor growth and development,therapeutic response); and (3) statistical decision making tools to make scientifically valid statementsrelated to key scientific hypotheses. The Biostatistics Core members will collaborate with projectinvestigators to interpret and synthesize study findings, and collaborate on the preparation of manuscripts.These collaborations will insure that the projects proposed will have high quality study designs andstatistical analysis plans that will provide a solid foundation for statistical models and inferences related tosignaling pathways in melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA114046-01A2
Application #
7445512
Study Section
Special Emphasis Panel (ZCA1-GRB-P (J1))
Project Start
2008-04-01
Project End
2013-03-31
Budget Start
2008-04-01
Budget End
2009-04-30
Support Year
1
Fiscal Year
2008
Total Cost
$119,435
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Hammerlindl, Heinz; Ravindran Menon, Dinoop; Hammerlindl, Sabrina et al. (2018) Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res 24:1090-1102
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Grasso, Michael; Estrada, Michelle A; Berrios, Kiara N et al. (2018) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. J Med Chem 61:5034-5046
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Emptage, Ryan P; Lemmon, Mark A; Ferguson, Kathryn M et al. (2018) Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure 26:1137-1143.e3
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705

Showing the most recent 10 out of 144 publications